Aclidinium bromide vs Umeclidinium

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline

Aclidinium bromide · Tudorza Pressair

Marketed by Azurity Pharmaceuticals and partners

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Partial signal

NCT00363896 · Phase 3 · completed

The trial randomized 843 participants to double-blind aclidinium or placebo, with trough FEV1 at 12 and 28 weeks, an accepted lung-function endpoint for COPD, as its primary outcome. The registry posts no significance test, but the publication of ACCLAIM/COPD I reports trough FEV1 improvements over placebo of 61 mL and 67 mL at 12 and 28 weeks (both p<0.001).

Reported efficacy

Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L. (met)

Result source: NCT03022097

Umeclidinium · Incruse Ellipta

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Reliable signal

NCT02184611 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 308 patients using lung function (trough FEV1) as its primary measure, and umeclidinium produced a significantly greater improvement than placebo (least-squares mean difference 0.154 L, 95% CI 0.113 to 0.194, p<0.001).

Reported efficacy

Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169 (Baseline (Day 1) and Day 169): Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001) (met)

Result source: NCT02184611

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAclidinium bromideUmeclidinium
Moderate or severe exacerbations, annualised rate0.4 vs 0.6−0.1 vs placebowk 52 · n 1791NCT01966107—Trial running · NCT06474039
Trough FEV1, change0.1 vs -0.1+0.2 vs placebo400/12 μg · wk 24 · n 262NCT03022097
25 other results
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg Bid · wk 24 · n 269 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 400/12 μg · wk 24 · n 335 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 1.2 vs 1.2 200 μg once-daily · wk 28 · n 594 · Phase 3 · primary NCT00358436
  • 1.2 vs 1.2 200 μg once-daily · wk 12 · n 594 · Phase 3 · primary NCT00358436
  • 0.1 vs -0.0 400µg · wk 12 · n 190 · Phase 3 · primary NCT00891462
  • 0.1 vs -0.0 400 μg · wk 12 · n 177 · Phase 3 · primary NCT01045161
  • 0.1 vs -0.0 400 μg Bid · wk 12 · n 269 · Phase 3 · primary NCT01001494
  • 0.0 vs -0.1 200 μg Bid · wk 24 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 200µg · wk 12 · n 184 · Phase 3 · primary NCT00891462
  • 0.0 vs -0.0 200 μg · wk 12 · n 182 · Phase 3 · primary NCT01045161
  • 0.0 vs -0.0 200 μg Bid · wk 12 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs 0.1 400/12 μg · wk 24 · n 314 · Phase 3 · primary NCT02796677
  • 0.0 vs -0.1 400/12 μg · wk 52 · n 335 · Phase 3 · secondary NCT01572792
  • 0.0 vs -0.1 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
  • 0.1 vs -0.0 wk 6 · n 86 · Phase 3 · secondary NCT00500318
  • 0.1 vs -0.0 400 μg bid · wk 3 · n 30 · Phase 4 · secondary NCT02153489
  • 0.1 vs -0.0 400 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 200 μg Bid · wk 1 · n 72 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 100 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
0.1 vs -0.0+0.2 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
21 other results
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12.14 · n 183 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 188 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12 · n 184 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 62.5 µg QD · wk 12.14 · n 178 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 62.5 µg QD · wk 12 · n 190 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 199 · Phase 3 · primary NCT02119286
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT02119286
  • 0.2 vs 0.1 62.5 mcg QD · wk 12.14 · n 392 · Phase 3 · primary NCT02207829
  • 0.2 vs 0.2 62.5/25 µg · wk 12.14 · n 392 · Phase 3 · primary NCT02257385
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.2 vs 0.0 62.5/25 mcg · wk 12 · n 227 · Phase 3 · secondary NCT02152605
  • 0.2 vs 0.1 62.5/25 mcg · wk 12.14 · n 349 · Phase 3 · secondary NCT01879410
  • 0.1 vs -0.0 62.5 mcg+ICS/LABA · wk 12 · n 109 · Phase 4 · primary NCT02257372
  • 0.1 vs -0.0 62.5/25 mcg · wk 24 · n 691 · Phase 4 · primary NCT03034915
  • 0.1 vs 0.1 62.5 mcg QD · wk 12 · n 431 · Phase 4 · primary NCT02236611
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
  • 0.2 vs -0.0 62.5/25 mcg · wk 12 · n 175 · Phase 4 · secondary NCT02275052
SGRQ total, change-8.7 vs -4.7−4 vs placebo400/12 μg · wk 24 · n 262NCT03022097
7 other results
  • -7.6 vs -4.7 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • -6.6 vs -2.2 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
  • -3.6 vs -1.9 400/12 μg · wk 52 · n 335 · Phase 3 · secondary NCT01572792
  • -5.5 vs -1.9 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
-6.2 vs -2.1−4 vs placebo62.5/25 mcg · wk 12 · n 212NCT02152605
5 other results
  • -7.3 vs -4.3 62.5 mcg · wk 24 · n 205 · Phase 3 · secondary NCT02184611
  • -7.0 vs -2.5 62.5 mcg · wk 12 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -1.4 62.5 mcg · wk 4 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
  • -5.0 vs -3.3 62.5/25 mcg · wk 24 · n 704 · Phase 4 · secondary NCT03034915
TDI focal score2.9 vs 2.1+0.8 vs placebo400/12 μg · wk 24 · n 262NCT03022097
5 other results
  • 2.6 vs 2.1 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • 2.0 vs 0.6 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
2.5 vs 1.6+0.9 vs placebo62.5 mcg · wk 24 · n 176NCT02184611

Moderate or severe exacerbations, annualised rate

Aclidinium bromide
0.4 vs 0.6−0.1 vs placebowk 52 · n 1791NCT01966107
Umeclidinium
—Trial running · NCT06474039

Trough FEV1, change

Aclidinium bromide
0.1 vs -0.1+0.2 vs placebo400/12 μg · wk 24 · n 262NCT03022097
25 other results
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg Bid · wk 24 · n 269 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 400/12 μg · wk 24 · n 335 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 1.2 vs 1.2 200 μg once-daily · wk 28 · n 594 · Phase 3 · primary NCT00358436
  • 1.2 vs 1.2 200 μg once-daily · wk 12 · n 594 · Phase 3 · primary NCT00358436
  • 0.1 vs -0.0 400µg · wk 12 · n 190 · Phase 3 · primary NCT00891462
  • 0.1 vs -0.0 400 μg · wk 12 · n 177 · Phase 3 · primary NCT01045161
  • 0.1 vs -0.0 400 μg Bid · wk 12 · n 269 · Phase 3 · primary NCT01001494
  • 0.0 vs -0.1 200 μg Bid · wk 24 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 200µg · wk 12 · n 184 · Phase 3 · primary NCT00891462
  • 0.0 vs -0.0 200 μg · wk 12 · n 182 · Phase 3 · primary NCT01045161
  • 0.0 vs -0.0 200 μg Bid · wk 12 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs 0.1 400/12 μg · wk 24 · n 314 · Phase 3 · primary NCT02796677
  • 0.0 vs -0.1 400/12 μg · wk 52 · n 335 · Phase 3 · secondary NCT01572792
  • 0.0 vs -0.1 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
  • 0.1 vs -0.0 wk 6 · n 86 · Phase 3 · secondary NCT00500318
  • 0.1 vs -0.0 400 μg bid · wk 3 · n 30 · Phase 4 · secondary NCT02153489
  • 0.1 vs -0.0 400 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 200 μg Bid · wk 1 · n 72 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 100 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
Umeclidinium
0.1 vs -0.0+0.2 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
21 other results
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12.14 · n 183 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 188 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12 · n 184 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 62.5 µg QD · wk 12.14 · n 178 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 62.5 µg QD · wk 12 · n 190 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 199 · Phase 3 · primary NCT02119286
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT02119286
  • 0.2 vs 0.1 62.5 mcg QD · wk 12.14 · n 392 · Phase 3 · primary NCT02207829
  • 0.2 vs 0.2 62.5/25 µg · wk 12.14 · n 392 · Phase 3 · primary NCT02257385
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.2 vs 0.0 62.5/25 mcg · wk 12 · n 227 · Phase 3 · secondary NCT02152605
  • 0.2 vs 0.1 62.5/25 mcg · wk 12.14 · n 349 · Phase 3 · secondary NCT01879410
  • 0.1 vs -0.0 62.5 mcg+ICS/LABA · wk 12 · n 109 · Phase 4 · primary NCT02257372
  • 0.1 vs -0.0 62.5/25 mcg · wk 24 · n 691 · Phase 4 · primary NCT03034915
  • 0.1 vs 0.1 62.5 mcg QD · wk 12 · n 431 · Phase 4 · primary NCT02236611
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
  • 0.2 vs -0.0 62.5/25 mcg · wk 12 · n 175 · Phase 4 · secondary NCT02275052

SGRQ total, change

Aclidinium bromide
-8.7 vs -4.7−4 vs placebo400/12 μg · wk 24 · n 262NCT03022097
7 other results
  • -7.6 vs -4.7 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • -6.6 vs -2.2 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
  • -3.6 vs -1.9 400/12 μg · wk 52 · n 335 · Phase 3 · secondary NCT01572792
  • -5.5 vs -1.9 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
Umeclidinium
-6.2 vs -2.1−4 vs placebo62.5/25 mcg · wk 12 · n 212NCT02152605
5 other results
  • -7.3 vs -4.3 62.5 mcg · wk 24 · n 205 · Phase 3 · secondary NCT02184611
  • -7.0 vs -2.5 62.5 mcg · wk 12 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -1.4 62.5 mcg · wk 4 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
  • -5.0 vs -3.3 62.5/25 mcg · wk 24 · n 704 · Phase 4 · secondary NCT03034915

TDI focal score

Aclidinium bromide
2.9 vs 2.1+0.8 vs placebo400/12 μg · wk 24 · n 262NCT03022097
5 other results
  • 2.6 vs 2.1 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • 2.0 vs 0.6 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
Umeclidinium
2.5 vs 1.6+0.9 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. Aclidinium bromide: 9 of 9 rows · Umeclidinium: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAclidinium bromide
Rows use multiple source trials
Umeclidinium
Rows use multiple source trials
E-RS Total
absolute change · score
-1.75 vs -0.73 placebo score @ 8wk400 μga,b,c
NCT02375724 · Phase 4 · registry result, not featured evidence
-1.52 vs -0.99 UMEC score @ 24wk62.5/25 mcga,b,c
NCT03034915 · Phase 4 · registry result, not featured evidence
Exercise Endurance Time Seconds
absolute value · seconds
68.3 vs 9.8 placebo seconds @ 3wk400 μg BIDd,a,b,e
NCT01471171 · Phase 3 · registry result, not featured evidence
-2.06 vs -5.37 placebo seconds @ 12wk62.5/25 mcgd,a,b,e
NCT02275052 · Phase 4 · registry result, not featured evidence
FRC Change
absolute change · L
-0.138 vs -0.076 placebo L @ 6wkd,a,b,f
NCT00500318 · Phase 3 · registry result, not featured evidence
-0.457 vs -0.111 placebo L @ 12wk62.5/25 mcgd,a,b,f
NCT02275052 · Phase 4 · registry result, not featured evidence
TDI Focal
absolute value · score
1.812 vs 0.731 placebo score @ 52wk400/12 μgg,d,a,b,h
NCT01572792 · Phase 3 · registry result, not featured evidence
show 1 more dose
1.742 vs 0.731 placebo score @ 52wk400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
1.68 vs 1.3 UMEC score @ 24wk62.5/25 mcgd,a,b,h
NCT03034915 · Phase 4 · registry result, not featured evidence
Time to First Moderate or Severe Exacerbation
time to event · months
NA vs NA placebo months @ 52wk200 μg once-dailya,b,i
NCT00358436 · Phase 3 · monotherapy
NA vs NA FF/VI + UMEC months100/62.5/25a,b,i
NCT02729051 · Phase 3 · registry result, not featured evidence
Dropout rate
14.2%200 μg Once-dailyj
NCT00363896 · Phase 3 · monotherapy
show 34 more results
25.7%200 μg once-daily
NCT00358436 · Phase 3 · monotherapy
7.1%400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.9%400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
—400 μg Bid
NCT01120093 · Phase 2
—200 μg Bid
NCT01120093 · Phase 2
—100 μg Bid
NCT01120093 · Phase 2
12.6%400µg
NCT00891462 · Phase 3
17.8%200µg
NCT00891462 · Phase 3
—400 μg
NCT01045161 · Phase 3
—400 μg
NCT01045161 · Phase 3
—200 μg
NCT01045161 · Phase 3
—200 μg to 400 μg
NCT01045161 · Phase 3
6.3%400 μg Bid
NCT01001494 · Phase 3
8.7%200 μg Bid
NCT01001494 · Phase 3
44.3%
NCT01966107 · Phase 4
4.4%400 μg
NCT02375724 · Phase 4 · registry result, not featured evidence
—400 μg bid
NCT02153489 · Phase 4 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
19.5%400/12 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
18.3%400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
19.5%400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
18.3%400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
8.8%400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
10.5%400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
—400 μg BID
NCT01471171 · Phase 3 · registry result, not featured evidence
2.9%400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
44.7%400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
42.6%200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
5.8%
NCT00500318 · Phase 3 · registry result, not featured evidence
—400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
13.7%62.5 mcgk
NCT02184611 · Phase 3
show 25 more results
8.9%125 µg QD
NCT01772147 · Phase 3 · combination
12.3%62.5 µg QD
NCT01772147 · Phase 3 · combination
5.3%62.5 µg
NCT01957163 · Phase 3 · combination
8.7%125 µg
NCT01957163 · Phase 3 · combination
3.4%125 µg
NCT02119286 · Phase 3 · combination
5.3%62.5 µg
NCT02119286 · Phase 3 · combination
10.7%125 µg QD
NCT01772134 · Phase 3 · combination
6.9%62.5 µg QD
NCT01772134 · Phase 3 · combination
11.7%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
—62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
5%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
8.4%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
5.7%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
8.3%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
4.6%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
7.3%62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
—62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
3.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
4.3%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
2.5%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
3.8%200 μg Once-dailyj
NCT00363896 · Phase 3 · monotherapy
show 34 more results
4.8%200 μg once-daily
NCT00358436 · Phase 3 · monotherapy
1.5%400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
1.1%400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
—400 μg Bid
NCT01120093 · Phase 2
—200 μg Bid
NCT01120093 · Phase 2
—100 μg Bid
NCT01120093 · Phase 2
3.7%400µg
NCT00891462 · Phase 3
4.3%200µg
NCT00891462 · Phase 3
—400 μg
NCT01045161 · Phase 3
—400 μg
NCT01045161 · Phase 3
—200 μg
NCT01045161 · Phase 3
—200 μg to 400 μg
NCT01045161 · Phase 3
1.5%400 μg Bid
NCT01001494 · Phase 3
2.9%200 μg Bid
NCT01001494 · Phase 3
—
NCT01966107 · Phase 4
1.5%400 μg
NCT02375724 · Phase 4 · registry result, not featured evidence
—400 μg bid
NCT02153489 · Phase 4 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
6.2%400/12 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
6.5%400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
6.2%400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
6.5%400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
3.1%400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
2.6%400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
—400 μg BID
NCT01471171 · Phase 3 · registry result, not featured evidence
1.8%400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
6.8%400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
7.1%200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
3.5%
NCT00500318 · Phase 3 · registry result, not featured evidence
—400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
2.4%62.5 mcgk
NCT02184611 · Phase 3
show 25 more results
3%125 µg QD
NCT01772147 · Phase 3 · combination
4.9%62.5 µg QD
NCT01772147 · Phase 3 · combination
1%62.5 µg
NCT01957163 · Phase 3 · combination
1.9%125 µg
NCT01957163 · Phase 3 · combination
1%125 µg
NCT02119286 · Phase 3 · combination
3.4%62.5 µg
NCT02119286 · Phase 3 · combination
4.9%125 µg QD
NCT01772134 · Phase 3 · combination
2.5%62.5 µg QD
NCT01772134 · Phase 3 · combination
3.6%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
—62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
1.9%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
5.9%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
2%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
2.5%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
3.2%62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
—62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
—100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
8%200 μg Once-dailyj
NCT00363896 · Phase 3 · monotherapy
show 34 more results
10.3%200 μg once-daily
NCT00358436 · Phase 3 · monotherapy
7.9%400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.2%400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
1.4%400 μg Bid
NCT01120093 · Phase 2
1.4%200 μg Bid
NCT01120093 · Phase 2
0%100 μg Bid
NCT01120093 · Phase 2
3.2%400µg
NCT00891462 · Phase 3
4.3%200µg
NCT00891462 · Phase 3
4.5%400 μg
NCT01045161 · Phase 3
9.5%400 μg
NCT01045161 · Phase 3
6%200 μg
NCT01045161 · Phase 3
13%200 μg to 400 μg
NCT01045161 · Phase 3
5.6%400 μg Bid
NCT01001494 · Phase 3
4.3%200 μg Bid
NCT01001494 · Phase 3
22.8%
NCT01966107 · Phase 4
1.5%400 μg
NCT02375724 · Phase 4 · registry result, not featured evidence
0%400 μg bid
NCT02153489 · Phase 4 · registry result, not featured evidence
7.3%400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
7.7%400/12 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
6.9%400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
5.7%400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
5.4%400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
6%400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
4.7%400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
0%400 μg BID
NCT01471171 · Phase 3 · registry result, not featured evidence
1.8%400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
10%400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
9.3%200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
12.3%400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
15.2%400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
14%200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
15.9%200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
2.3%
NCT00500318 · Phase 3 · registry result, not featured evidence
0%400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
8.3%62.5 mcgk
NCT02184611 · Phase 3
show 25 more results
3%125 µg QD
NCT01772147 · Phase 3 · combination
3%62.5 µg QD
NCT01772147 · Phase 3 · combination
1%62.5 µg
NCT01957163 · Phase 3 · combination
3.4%125 µg
NCT01957163 · Phase 3 · combination
1.4%125 µg
NCT02119286 · Phase 3 · combination
3.9%62.5 µg
NCT02119286 · Phase 3 · combination
2.9%125 µg QD
NCT01772134 · Phase 3 · combination
2%62.5 µg QD
NCT01772134 · Phase 3 · combination
6%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
3%62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
3.3%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
5%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
10.4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
3.3%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
4.4%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
6.9%62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
3.2%62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
0.5%62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
1.7%62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
0.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
200 μg Once-dailyj
nasopharyngitis 16.3% (placebo 14.4%)
headache 11.3% (placebo 12.5%)
back pain 4.8% (placebo 4.6%)
NCT00363896 · Phase 3 · monotherapy
show 34 more results
200 μg once-daily
headache 14.2% (placebo 12.7%)
nasopharyngitis 12.7% (placebo 11.3%)
upper respiratory tract infection 10.8% (placebo 9.8%)
NCT00358436 · Phase 3 · monotherapy
400 μg
upper respiratory tract infection 9.4% (placebo 8.9%)
chronic obstructive pulmonary disease 7.9% (placebo 13%)
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
upper respiratory tract infection 11.8% (placebo 8.9%)
chronic obstructive pulmonary disease 9.5% (placebo 13%)
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400 μg Bid
headache 6.8% (placebo 1.3%)
NCT01120093 · Phase 2
200 μg Bid
headache 5.5% (placebo 1.3%)
NCT01120093 · Phase 2
100 μg Bid
headache 5.5% (placebo 1.3%)
NCT01120093 · Phase 2
400µg
chronic obstructive pulmonary disease 7.4% (placebo 12.4%)
NCT00891462 · Phase 3
200µg
chronic obstructive pulmonary disease 9.2% (placebo 12.4%)
NCT00891462 · Phase 3
400 μg
copd exacerbation 13% (placebo 11.5%)
upper respiratory tract infection 1.7% (placebo 0.5%)
nasopharyngitis 1.1% (placebo 0%)
NCT01045161 · Phase 3
400 μg
copd exacerbation 27.9% (placebo 11.5%)
upper respiratory tract infection 5.4% (placebo 0.5%)
nasopharyngitis 4.1% (placebo 0%)
NCT01045161 · Phase 3
200 μg
copd exacerbation 8.7% (placebo 11.5%)
upper respiratory tract infection 1.6% (placebo 0.5%)
nasopharyngitis 1.1% (placebo 0%)
NCT01045161 · Phase 3
200 μg to 400 μg
copd exacerbation 22.7% (placebo 11.5%)
nasopharyngitis 5.8% (placebo 0%)
upper respiratory tract infection 5.8% (placebo 0.5%)
NCT01045161 · Phase 3
400 μg Bid
chronic obstructivce pulmonary disease 14.1% (placebo 20.5%)
headache 12.3% (placebo 8.1%)
nasopharyngitis 11.2% (placebo 8.4%)
NCT01001494 · Phase 3
200 μg Bid
chronic obstructivce pulmonary disease 15.9% (placebo 20.5%)
nasopharyngitis 11.6% (placebo 8.4%)
headache 10.8% (placebo 8.1%)
NCT01001494 · Phase 3
urinary tract infection 5% (placebo 4.7%)
upper respiratory tract infection 4.8% (placebo 5.6%)
viral upper respiratory tract infection 4.4% (placebo 3.7%)
NCT01966107 · Phase 4
400 μg
headache 5.2% (placebo 9.7%)
nasopharyngitis 3% (placebo 6.7%)
NCT02375724 · Phase 4 · registry result, not featured evidence
400 μg bid
erythema 10% (placebo 0%)
NCT02153489 · Phase 4 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary 15.6%
nasopharyngitis 11.5%
headache 5.1%
NCT02796677 · Phase 3 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary disease 20.3% (placebo 15.8%)
urinary tract infection 8.2% (placebo 5.5%)
nasopharyngitis 7.7% (placebo 4.8%)
NCT01572792 · Phase 3 · registry result, not featured evidence
400/6 μg
chronic obstructive pulmonary disease 22.1% (placebo 15.8%)
nasopharyngitis 6.9% (placebo 4.8%)
urinary tract infection 6.4% (placebo 5.5%)
NCT01572792 · Phase 3 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary disease 15.2% (placebo 17.5%)
cough 5.1% (placebo 3.6%)
nasopharyngitis 4.8% (placebo 3.6%)
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
400/6 μg
chronic obstructive pulmonary disease 14.7% (placebo 17.5%)
nasopharyngitis 5.1% (placebo 3.6%)
cough 3.9% (placebo 3.6%)
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
chronic obstructive pulmonary disease 8.6% (placebo 11.9%)
nasopharyngitis 7.8% (placebo 7.2%)
headache 7.5% (placebo 8.2%)
NCT01462942 · Phase 3 · registry result, not featured evidence
400/6 μg
chronic obstructive pulmonary disease 9.4% (placebo 11.9%)
nasopharyngitis 7.9% (placebo 7.2%)
headache 7.1% (placebo 8.2%)
NCT01462942 · Phase 3 · registry result, not featured evidence
400 μg BID
nasopharyngitis 6.3% (placebo 3.7%)
NCT01471171 · Phase 3 · registry result, not featured evidence
400 µg BID
nasopharyngitis 6.4% (placebo 2.4%)
headache 3.5% (placebo 4.7%)
NCT01462929 · Phase 3 · registry result, not featured evidence
400µg
chronic obstructive pulmonary disease 19.9%
NCT01044459 · Phase 3 · registry result, not featured evidence
200µg
chronic obstructive pulmonary disease 19.3%
NCT01044459 · Phase 3 · registry result, not featured evidence
400 μg
chronic obstructive pulmonary disorder 22.6%
nasopharyngitis 9.4%
urinary tract infection 7.5%
NCT00970268 · Phase 3 · registry result, not featured evidence
400 μg
chronic obstructive pulmonary disorder 30.4%
contusion 10.9%
cough 8.7%
NCT00970268 · Phase 3 · registry result, not featured evidence
200 μg
chronic obstructive pulmonary disorder 24.7%
nasopharyngitis 8.6%
back pain 7.5%
NCT00970268 · Phase 3 · registry result, not featured evidence
200 μg
chronic obstructive pulmonary disorder 36.4%
sinusitis 11.4%
upper respiratory tract infection 11.4%
NCT00970268 · Phase 3 · registry result, not featured evidence
cough 5.8% (placebo 3.2%)
headache 5.8% (placebo 7.4%)
upper respiratory tract infection 5.8% (placebo 2.1%)
NCT00500318 · Phase 3 · registry result, not featured evidence
400 μg Bid
diarrhoea 6.9% (placebo 0%)
chronic obstructive pulmonary disease 0% (placebo 10%)
NCT00868231 · Phase 2 · registry result, not featured evidence
62.5 mcgk
upper respiratory tract infection 12.2% (placebo 12.9%)
nasopharyngitis 9.3% (placebo 10.9%)
dizziness 2.9% (placebo 2%)
NCT02184611 · Phase 3
show 23 more results
125 µg QD
nasopharyngitis 5% (placebo 4.5%)
headache 3% (placebo 4.5%)
NCT01772147 · Phase 3 · combination
62.5 µg QD
headache 4.4% (placebo 4.5%)
nasopharyngitis 3% (placebo 4.5%)
NCT01772147 · Phase 3 · combination
62.5 µg
headache 4.4% (placebo 2.9%)
back pain 3.4% (placebo 1.5%)
nasopharyngitis 3.4% (placebo 3.4%)
NCT01957163 · Phase 3 · combination
125 µg
nasopharyngitis 4.8% (placebo 3.4%)
headache 4.3% (placebo 2.9%)
cough 3.4% (placebo 0.5%)
NCT01957163 · Phase 3 · combination
125 µg
nasopharyngitis 9.2% (placebo 10.7%)
headache 1.9% (placebo 2.4%)
back pain 1% (placebo 1.9%)
NCT02119286 · Phase 3 · combination
62.5 µg
nasopharyngitis 5.3% (placebo 10.7%)
back pain 3.9% (placebo 1.9%)
headache 3.9% (placebo 2.4%)
NCT02119286 · Phase 3 · combination
125 µg QD
headache 6.3% (placebo 4.9%)
cough 2.4% (placebo 1.5%)
nasopharyngitis 2.4% (placebo 4.9%)
NCT01772134 · Phase 3 · combination
62.5 µg QD
headache 4.4% (placebo 4.9%)
cough 3.4% (placebo 1.5%)
nasopharyngitis 2.5% (placebo 4.9%)
NCT01772134 · Phase 3 · combination
62.5/25 mcg
nasopharyngitis 8.4%
NCT03034915 · Phase 4 · registry result, not featured evidence
62.5 mcg QD
headache 8.1%
nasopharyngitis 8.1%
NCT02236611 · Phase 4 · registry result, not featured evidence
62.5 mcg+ICS/LABA
nasopharyngitis 13.4% (placebo 14.5%)
headache 3.4% (placebo 6.8%)
cough 2.5% (placebo 4.3%)
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
100/62.5/25
viral upper respiratory tract infection 10.6%
headache 6.1%
upper respiratory tract infection 3.4%
NCT02729051 · Phase 3 · registry result, not featured evidence
62.5 mcg QD
headache 5.9%
nasopharyngitis 5.3%
NCT02207829 · Phase 3 · registry result, not featured evidence
62.5/25 µg
headache 7.5%
nasopharyngitis 6.6%
cough 3.3%
NCT02257385 · Phase 3 · registry result, not featured evidence
62.5/25mcg
headache 6.5% (placebo 6.5%)
nasopharyngitis 5.2% (placebo 6.5%)
NCT02152605 · Phase 3 · registry result, not featured evidence
62.5/25 mcg
headache 6.9%
nasopharyngitis 4%
NCT01879410 · Phase 3 · registry result, not featured evidence
62.5/25 µg
headache 5%
NCT02014480 · Phase 3 · registry result, not featured evidence
62.5/25 µg once daily
nasopharyngitis 4%
headache 3.5%
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
100/250 µg
nasopharyngitis 1.9%
toothache 0.5%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/125 µg
dysphonia 6.5%
nasopharyngitis 4.3%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/15.6 µg
nasopharyngitis 7.1%
toothache 7.1%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/62.5 µg
nasopharyngitis 5%
dysphonia 2.5%
toothache 2.5%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/250/25 µg
dysphonia 0%
nasopharyngitis 0%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 24 weeks versus 8 weeks.
  4. dTrial phases differ: Phase 4 versus Phase 3.
  5. eAssessment timepoints differ: 12 weeks versus 3 weeks.
  6. fAssessment timepoints differ: 12 weeks versus 6 weeks.
  7. gThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  8. hAssessment timepoints differ: 24 weeks versus 52 weeks.
  9. iThe assessment timepoint is not available for both results.
  10. jPopulation comparability has not been reviewed for 31 of these studies.
  11. kPopulation comparability has not been reviewed for 25 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aclidinium bromide

FEV1 Trough 1.422 vs 1.356 placebo L @ 28wk200 μg Once-daily
absolute value · L
NCT00363896 · Phase 3 · monotherapy
show 1 more result
1.428 vs 1.366 placebo L @ 12wk200 μg Once-daily
NCT00363896 · Phase 3 · monotherapy
Time to First Exacerbation NA vs NA placebo months @ 52wk200 μg Once-daily
time to event · months
NCT00363896 · Phase 3 · monotherapy
SGRQ 57.3% (n=269) vs 41% (n=271) placebo @ 24wk400 μg Bid
responder rate · % of participants
Yes (% Patients with 4-unit decrease)
NCT01001494 · Phase 3
show 3 more results
48.1% (n=591) vs 39.5% (n=200) placebo @ 52wk200 μg Once-daily
Yes (% Patients with 4-unit decrease)
NCT00363896 · Phase 3 · monotherapy
39% (n=574) vs 32.8% (n=195) placebo @ 52wk200 μg once-daily
Yes (% Patients with 4-unit decrease)
NCT00358436 · Phase 3 · monotherapy
56% (n=275) vs 41% (n=271) placebo @ 24wk200 μg Bid
Yes (% Patients with 4-unit decrease)
NCT01001494 · Phase 3
FEV1 Change 1h 0.248 vs -0.05 placebo L @ 24wk400/12 μg
absolute change · L
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 8 more results
0.156 vs -0.05 placebo L @ 24wk400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
0.253 vs 0.169 AB L @ 24wk400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
0.198 vs -0.086 placebo L @ 52wk400/12 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
0.166 vs -0.086 placebo L @ 52wk400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
0.247 vs -0.037 placebo L @ 24wk400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
0.226 vs -0.037 placebo L @ 24wk400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
0.269 vs -0.03 placebo L @ 24wk400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
0.213 vs -0.03 placebo L @ 24wk400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
FEV1 Peak 0.324 vs 0.008 placebo L @ 24wk400/12 μg
absolute change · L
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 8 more results
0.225 vs 0.008 placebo L @ 24wk400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
0.263 vs 0.071 placebo L @ 12wk400µg
NCT00891462 · Phase 3
0.212 vs 0.087 placebo L @ 12wk400 μg
NCT01045161 · Phase 3
0.231 vs 0.022 placebo L @ 24wk400 μg Bid
NCT01001494 · Phase 3
0.1605 vs -0.0149 placebo L @ 3wk400 μg bid
NCT02153489 · Phase 4 · registry result, not featured evidence
0.217 vs 0.071 placebo L @ 12wk200 µg
NCT00891462 · Phase 3
0.202 vs 0.087 placebo L @ 12wk200 μg
NCT01045161 · Phase 3
0.206 vs 0.022 placebo L @ 24wk200 μg Bid
NCT01001494 · Phase 3
FEV1 AUC0-12h 0.183 vs -0.026 placebo L @ 1wk400 μg Bid
absolute change · L
NCT01120093 · Phase 2
show 4 more results
0.236 vs 0.015 placebo L @ 2.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.23 vs 0.016 placebo L @ 0.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.151 vs -0.026 placebo L @ 1wk200 μg Bid
NCT01120093 · Phase 2
0.128 vs -0.026 placebo L @ 1wk100 μg Bid
NCT01120093 · Phase 2
FEV1 AUC 12-24h 0.086 vs -0.103 placebo L @ 1wk400 μg Bid
absolute change · L
NCT01120093 · Phase 2
show 5 more results
0.032 vs -0.128 placebo L @ 6wk400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
0.174 vs -0.032 placebo L @ 2.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.202 vs -0.06 placebo L @ 0.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.047 vs -0.103 placebo L @ 1wk200 μg Bid
NCT01120093 · Phase 2
0.044 vs -0.103 placebo L @ 1wk100 μg Bid
NCT01120093 · Phase 2
FEV1 AUC(0-24h 0.133 vs -0.062 placebo L @ 1wk400 μg Bid
absolute change · L
NCT01120093 · Phase 2
show 5 more results
0.065 vs -0.085 placebo L @ 6wk400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
0.226 vs -0.006 placebo L @ 2.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.211 vs -0.024 placebo L @ 0.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.1 vs -0.062 placebo L @ 1wk200 μg Bid
NCT01120093 · Phase 2
0.088 vs -0.062 placebo L @ 1wk100 μg Bid
NCT01120093 · Phase 2
FEV1 Trough 0.048 L @ 52wk400 μg
absolute change · L
No placebo or comparator arm
NCT01045161 · Phase 3
show 3 more results
0.072 L @ 52wk400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
0.029 L @ 52wk200 μg to 400 μg
NCT01045161 · Phase 3
0.034 L @ 52wk200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
FEV1 Peak 0.172 L @ 52wk400 μg
absolute change · L
No placebo or comparator arm
NCT01045161 · Phase 3
show 3 more results
0.214 L @ 52wk400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
0.176 L @ 52wk200 μg to 400 μg
NCT01045161 · Phase 3
0.185 L @ 52wk200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
TDI Focal 56.9% (n=262) vs 45.5% (n=257) placebo @ 24wk400 μg Bid
responder rate · % of participants
Yes (% Patients with a 1-unit decrease)
NCT01001494 · Phase 3
show 1 more result
53.3% (n=270) vs 45.5% (n=257) placebo @ 24wk200 μg Bid
Yes (% Patients with a 1-unit decrease)
NCT01001494 · Phase 3
Moderate or Severe Exacerbation Rate Annualized 0.44 vs 0.57 placebo per year @ 52wk
event rate · per year
NCT01966107 · Phase 4

+ 22 further endpoints in the CSV export.

Umeclidinium

FEV1 Wm0 6 h 0.136 vs 0.011 placebo L @ 0wk62.5 mcg
absolute change · L
NCT02184611 · Phase 3
show 10 more results
0.187 vs 0.034 placebo L @ 12wk62.5 µg
NCT01957163 · Phase 3 · combination
0.184 vs 0.035 placebo L @ 12wk62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
0.235 vs 0.258 Indacaterol + Tiotropium Bromide L @ 12wk62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
0.217 vs 0.052 placebo L @ 12wk125 µg QD
NCT01772147 · Phase 3 · combination
0.175 vs 0.034 placebo L @ 12wk125 µg
NCT01957163 · Phase 3 · combination
0.192 vs 0.032 placebo L @ 12wk125 µg QD
NCT01772134 · Phase 3 · combination
0.196 vs 0.052 placebo L @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
0.196 vs 0.032 placebo L @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
0.152 vs 0.017 placebo L @ 12wk125 µg
NCT02119286 · Phase 3 · combination
0.164 vs 0.017 placebo L @ 12wk62.5 µg
NCT02119286 · Phase 3 · combination
CAT Total -1.75 vs -0.26 placebo score @ 4wk62.5 mcg
absolute change · score
NCT02184611 · Phase 3
show 2 more results
-2.18 vs -0.08 placebo score @ 12wk62.5 mcg
NCT02184611 · Phase 3
-2 vs -1.32 placebo score @ 24wk62.5 mcg
NCT02184611 · Phase 3
Rescue-free 24-h Period 15.2 vs 1.9 placebo % of time @ 12wk125 µg QD
percent change · % of time
NCT01772147 · Phase 3 · combination
show 1 more result
8.4 vs 1.9 placebo % of time @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
Rescue Puffs -0.7 vs -0.2 placebo puffs @ 12wk125 µg QD
absolute change · puffs
NCT01772147 · Phase 3 · combination
show 3 more results
-0.5 vs -0.2 placebo puffs @ 12wk125 µg QD
NCT01772134 · Phase 3 · combination
-0.4 vs -0.2 placebo puffs @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
-0.5 vs -0.2 placebo puffs @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
Rescue-free 24 h Periods 11.1 vs 4.9 placebo % of time @ 12wk125 µg QD
absolute change · % of time
NCT01772134 · Phase 3 · combination
show 1 more result
13.3 vs 4.9 placebo % of time @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
TDI Focal 50% (n=806) vs 42% (n=799) UMEC @ 24wk62.5/25 mcg
responder rate · % of participants
NCT03034915 · Phase 4 · registry result, not featured evidence
show 1 more result
56% (n=482) vs 56% (n=481) FF/VI + UMEC @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
E-RS Cough Sputum Domain -0.45 vs -0.38 UMEC score @ 24wk62.5/25 mcg
absolute change · score
RS-CSP
NCT03034915 · Phase 4 · registry result, not featured evidence
E-RS 36% (n=809) vs 27% (n=800) UMEC @ 24wk62.5/25 mcg
responder rate · % of participants
NCT03034915 · Phase 4 · registry result, not featured evidence
SGRQ 45% (n=811) vs 41% (n=802) UMEC @ 24wk62.5/25 mcg
responder rate · % of participants
NCT03034915 · Phase 4 · registry result, not featured evidence
show 1 more result
50% (n=489) vs 51% (n=483) FF/VI + UMEC @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
CAT -3.5 vs -3.4 UMEC score @ 24wk62.5/25 mcg
absolute change · score
NCT03034915 · Phase 4 · registry result, not featured evidence
CAT 55% (n=812) vs 48% (n=804) UMEC @ 24wk62.5/25 mcg
responder rate · % of participants
NCT03034915 · Phase 4 · registry result, not featured evidence
IC Change 0.225 vs -0.034 placebo L @ 12wk62.5/25 mcg
absolute change · L
NCT02275052 · Phase 4 · registry result, not featured evidence

+ 7 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide's landscape · Umeclidinium's landscape